References
- Rudiger T, Weisenburger DD, Anderson JR, et al. Peripheral T-cell lymphoma: results from the Non-Hodgkin’s Lymphoma classification project. Ann Oncol 2002;13:140–149.
- Greer JP. Therapy of peripheral T/NK neoplasms. Hematology Am Soc Hematol Educ Program 2006:331–337.
- Weiss LM, Jaffe ES, Liu XF, et al. Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Blood 1992;79:1789–1795.
- Steinberg AD, Seldin MF, Jaffe ES, et al. NIH conference. angioimmunoblastic lymphadenopathy with dysproteinemia. Ann Intern Med 1988;108:575–584.
- Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood 1998;92:76–82.
- Kyriakou C, Canals C, Goldstone A, et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26:218–224.
- Tsai DE, Aqui NA, Vogl DT, et al. Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid analog bexarotene. Am J Transplant 2005;5:2070–2073.
- Boehm M, Zhang M, Badea B, et al. Synthesis and structure-activity relationship of novel retinoid X receptor-selective retinoids. J Med Chem 1994;37:2930–2941.
- Duvic M, Hymes K, Hearld P, et al. Bexarotene is effective and safe for treatment of refractory advanced stage cutaneous T cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19:2456–2471.
- Tsai DE, Luger SM, Andreadis C, et al. A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia. Clin Cancer Res 2008;14:5619–5625.
- Esteva F, Glaspy J, Baidas S, et al. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol 2003;21:999–1006.